Sharon Taft-Benz

3 weeks ago | biorxiv.org | John Sears |Durbadal Ojha |Sharon Taft-Benz |Paul Sylvester

AbstractAlphaviruses are mosquito-borne viruses that have caused significant outbreaks in the 21st century. Despite multiple recent outbreaks, there are no approved antiviral drugs to treat any alphavirus infection. Therefore, developing broadly acting antiviral drugs effective against multiple alphaviruses is necessary and could provide protection from both current and emerging alphavirus threats.

1 month ago | pubs.acs.org | Mohammad Hossain |Anirban Ghoshal |Sharon Taft-Benz

IntroductionClick to copy section linkSection link copied!Covalent enzyme inhibitors have been developed as effective direct acting drugs to combat viral infections. (1) Examples include nirmatrelvir, which targets the main cysteine protease of SARS-CoV-2 and is used to treat COVID-19. (2) Likewise, boceprevir, and narlaprevir are covalent inhibitors of hepatitis C virus (HCV) NS3/4A serine protease and are effective in the treatment of chronic HCV infections.